Boston Scientific Jones and Dunkin detail why Apollo tech could launch endosurgery revolution

DeviceTalks

This episode of Boston Scientific Talks features Boston Scientific's entrance into advanced endoluminal surgery and obesity management, spearheaded by its acquisition of Apollo Endosurgery in November 2022. Chief Medical Officer, Endoscopy Brian Dunkin, MD and SVP and President, Endoscopy Mike Jones explore the strategic value of this acquisition and the integration of Apollo's technology, which is poised to potentially revolutionize endoscopic procedures. The discussion centers on the potential of Apollo's technology in broadening Boston Scientific's endoluminal surgery capabilities. Jones highlights the addition of the Overstitch device, which enhances the company's ability to perform endoscopic suturing and endoluminal sleeve gastroplasty, addressing obesity through minimally invasive means. Additionally, Dr. Dunkin provides a clinical perspective on how these technologies represent a paradigm shift in surgery, moving towards scarless operations. They also explore the role of GLP-1 medications in the medical device market, underlining how pharmaceuticals complement devices in obesity treatment. The episode gives a comprehensive view of Boston Scientific's strategy in integrating Apollo's technology into its portfolio, the challenges of training and adoption, and the optimism for future innovations in minimally invasive procedures. Thank you to Freudenberg Medical for sponsoring this episode. Please visit Freudenberg Medical’s dedicated webpage at https://www.freudenbergmedical.com/en/single-use-scopes/ to learn more about their specific expertise in this area and to access Freudenberg Medical’s trend paper on the topic. Thank you for listening to the Boston Scientific Podcast. Subscribe to this podcast on every major podcast platform, https://linktr.ee/DeviceTalks